System and method for promoting coronary angiogenesis

• US 7,751,883 B2
• Filed: 04/25/2006
• Issued: 07/06/2010
• Est. Priority Date: 04/25/2006
• Status: Active Grant

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Eugenio Picano
• Inventors: Picano, Eugenio
• Primary Examiner(s): Evanisko; George R
• Assistant Examiner(s): EL-KAISSI, HIBA CARINE
• Application Number:
  US11/380,048
• Publication Number:
  US 20070249558A1
• Time in Patent Office: 1,533 Days
• Field of Search: 607/1, 607/2, 607/3, 607/4, 607/5, 607/9, 607/14, 607/120, 607/122, 623/1.42
• US Class Current: 607/9
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61N 1/3629 in combination with non-electric therapy

Abstract

Systems and methods for promoting coronary angiogenesis employ a combination of mechanical, metabolic and biochemical stimuli.

Claims

1. A medical system configured to promote coronary angiogenesis in a patient, the system comprising:

an implantable medical electrical pacing lead including at least one electrode, the at least one electrode being adapted to deliver cardiac pacing stimuli, when the pacing lead is implanted in the patient;

a first fluid reservoir and a plurality of boluses of heparin, the first fluid reservoir containing the plurality of boluses of heparin;

a first pump being coupled to the first fluid reservoir and being adapted to pump each bolus of heparin from the first reservoir;

a second fluid reservoir and a plurality of boluses of an adenosine-modulating drug, the second fluid reservoir containing the plurality of boluses of the adenosine-modulating drug;

a second pump being coupled to the second fluid reservoir and being adapted to pump each bolus of the adenosine-modulating drug from the second reservoir;

a delivery tube coupled to the first reservoir and to the second reservoir, the delivery tube being adapted to deliver the boluses of the heparin and the adenosine-modulating drug into a venous system of the patient; and

a microcomputer unit coupled to the pacing lead and to each of the first and second pumps, the microcomputer unit being programmed with instructions to control the lead and the pumps in order to execute a method for delivering angiogenic therapy according to the following steps;

delivering a bolus of heparin through the delivery tube and into the venous system of the patient, the bolus of heparin being pumped, by the first pump, from the plurality of boluses of heparin contained in the first fluid reservoir;

delivering the cardiac pacing stimuli via the at least one electrode of the implanted pacing lead for a predetermined period of time and at a rate that generally provokes myocardial ischemia in the patient, after delivering of the bolus of heparin; and

delivering a bolus of the adenosine-modulating drug through the implanted delivery tube, and into the venous system of the patient, after delivering the pacing stimuli, the bolus of the adenosine-modulating drug being pumped, by the second pump, from the plurality of boluses of the adenosine-modulating drug contained in the second fluid reservoir.

2. The system of claim 1, further comprising:

an implantable housing including a sidewall and containing the first and second pumps, the first and second fluid reservoirs, and the microcomputer unit;

at least one feedthrough, extending through the housing sidewall, for electrical coupling of the lead to the microcomputer unit; and

at least one passageway, extending through the housing sidewall, for coupling the delivery tube to the pump.

3. The system of claim 2, further comprising a fill port mounted in the housing sidewall and coupled to each of the first and second fluid reservoirs, the fill port being accessible transcutaneously.

4. The system of claim 1, wherein the delivery tube is implantable.

5. The system of claim 1, wherein:

the delivered bolus of heparin is approximately 5,000 units; and

the microcomputer unit is programmed to control the lead and the pumps so that the bolus of heparin is delivered approximately five minutes prior to delivering the predetermined period of the pacing stimuli.

6. The system of claim 1, wherein:

the adenosine-modulating drug is dipyridamole and the delivered bolus of dipyridamole is approximately 10 milligrams; and

the microcomputer unit is programmed to control the lead and the pumps so that the bolus of dipyridamole is delivered approximately one minute after delivering the pacing stimuli for the predetermined period of time.

7. The system of claim 1, wherein the predetermined period of time for delivery of the pacing stimuli is between approximately 5 minutes and approximately 30 minutes.

8. The system of claim 1, wherein the microcomputer unit is programmed to control the lead and the pumps so that the sequence of steps of delivering the bolus of heparin, delivering the pacing stimuli and delivering the bolus of adenosine-modulating drug are repeated twice a day.

9. The system of claim 1, wherein the microcomputer unit is programmed to control the lead and the pumps so that the sequence of steps of delivering the bolus of heparin, delivering the pacing stimuli and delivering the bolus of adenosine-modulating drug are repeated at least once a day for between approximately ten and approximately fifteen days.